mild cognitive impairment

Overview

Mild cognitive impairment (MCI) is a clinical syndrome characterized by measurable cognitive decline that is greater than expected for age but does not yet meet criteria for dementia. It is commonly described as an intermediate state between normal cognitive aging and dementia, and it is often used in research and clinical practice as a prodromal or risk state for neurodegenerative disease, especially Alzheimer disease. Individuals with MCI may have isolated memory impairment or deficits in other cognitive domains, while daily functional independence is largely preserved.

Biologically and medically, MCI is important because it is a major target for early detection, risk stratification, and intervention. Recent research has linked MCI to Alzheimer disease-related pathology, vascular brain injury, obstructive sleep apnoea, hearing loss, type 2 diabetes, and broader brain-aging exposures. It is also a frequent endpoint in studies of biomarkers, imaging, digital health tools, and preventive therapies aimed at slowing progression to dementia or improving cognitive and functional outcomes.

Recent Publications Focus

Below is a summary of the newest research publications targeting mild cognitive impairment (sorted by publication date).

Recent studies have examined mild cognitive impairment across a broad range of clinical, biomarker, and computational approaches. One target-trial emulation compared initiation of the monoclonal antibody lecanemab with acetylcholinesterase inhibitors in patients with mild cognitive impairment or Alzheimer's disease, focusing on real-world safety and effectiveness. Other work has explored whether circulating molecular profiles can help characterize disease risk: a population-based longitudinal study identified a plasma proteomics and metabolomics signature associated with prevalent and new-onset mild cognitive impairment and dementia, with a 10-variable predictive model including proteins, fatty acids, and inflammatory markers. In parallel, a fully automated plasma kallikrein-8 immunoassay was evaluated as a potential biomarker for early diagnosis at the mild cognitive impairment stage.

Several publications focused on neurophysiologic and neuroanatomic correlates of mild cognitive impairment. A Transformer-based EEG model was trained to detect mild cognitive impairment and achieved 75.4% average accuracy in five-fold cross-validation, generalized to Alzheimer's disease cohorts and an external clinical center, and produced risk scores that correlated with Montreal Cognitive Assessment subdomains. The model’s decision process was linked to interpretable electrophysiological features and cortical regions, including the insular cortex and transverse temporal regions. Another study investigated hypothalamic microstructure and function in aging, reporting associations between hypothalamic subregional alterations and cognitive and functional decline in mild cognitive impairment. exercise-related physiology was also examined: one study assessed plasma myokine and cytokine responses after a 6-minute walking exercise and found a suppressed brain-derived neurotrophic factor response in mild cognitive impairment.

Intervention-oriented and prognostic studies also featured prominently. A cost-effectiveness analysis evaluated SMART4MD, a customized tablet app designed to improve or maintain quality of life for people with mild cognitive impairment and their informal caregivers. A protocol for the SOUND trial proposed a family-supported hearing aid use behavior intervention for older adults with hearing loss and mild cognitive impairment, aiming to improve cognitive function. In addition, a protocol for Tongxinluo capsule in cerebral small vessel disease planned to test whether the treatment could benefit Chinese patients with mild cognitive impairment. For prognosis, a dual-model deep learning framework using a single baseline cerebrospinal fluid biomarker assessment was developed to estimate cognitive decline and time-to-conversion from mild cognitive impairment to dementia, with strong performance and uncertainty quantification across a large multicenter dataset.

Other recent work linked mild cognitive impairment to metabolic disease and therapeutic comparisons. A real-world retrospective cohort study compared tirzepatide with semaglutide for prevention of mild cognitive impairment, dementia, and Alzheimer's disease in type 2 diabetes, reflecting growing interest in glucagon-like peptide-1 agonists and related dementia outcomes. Across these studies, mild cognitive impairment is being used both as a clinical target for early detection and as a key transition point for evaluating progression, prognosis, and intervention effects.

Background PMIDs

[PMID 41570392]
[PMID 41587770]
[PMID 41708563]
[PMID 41770546]
[PMID 41855851]
[PMID 41863264]
[PMID 41914924]
[PMID 41933172]
[PMID 41933718]
[PMID 42128444]
[PMID 42133909]
[PMID 42133953]
[PMID 42155113]
[PMID 42165911]
[PMID 42166837]
[PMID 42168722]
[PMID 42217083]
[PMID 42314102]
[PMID 42341295]
[PMID 42372258]
[PMID 42373182]

Method PMIDs

[PMID 42411051]

Target PMIDs

[PMID 40935402]
[PMID 41819517]
[PMID 41825212]
[PMID 41912101]
[PMID 41962454]
[PMID 42092705]
[PMID 42156151]
[PMID 42172614]
[PMID 42229510]
[PMID 42303781]
[PMID 42332768]

Conclusion PMIDs

[PMID 42166837]